Meyer Children's Hospital IRCCS

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Meyer Children's Hospital IRCCS sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 5 currently recruiting upper quartile by trial count

Meyer Children's Hospital IRCCS: 6 sponsored US clinical trials, 5 recruiting.

Meyer Children's Hospital IRCCS sponsors 6 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting. The most-studied condition in this pipeline is Eosinophilic Fasciitis, with 1 trials.

Upper-quartile sponsor footprint

Meyer Children's Hospital IRCCS sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Meyer Children's Hospital IRCCS pipeline

5 recruiting of 6 indexed (83% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Eosinophilic Fasciitis (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Meyer Children's Hospital IRCCS: open-pipeline peers nationwide

Peers matched on 6 registered trials and 83% open enrollment, not the therapeutic-area sidebar.

Meyer Children's Hospital IRCCS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 5.566.577.5 0%20%40%60%80%100% Total trials Recruiting share Meyer Children's Hospital IRCCS23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchCentessa Pharmaceuticals (UK) LimitedSystImmuneTyra BiosciencesJohnson & Johnson Enterprise Innovation
Meyer Children's Hospital IRCCS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Meyer Children's Hospital IRCCS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 83% open enrollment (± trial volume)

What to do with this Meyer Children's Hospital IRCCS page

6 registered trials is a research-attention snapshot, not an endorsement of Meyer Children's Hospital IRCCS or any single study.

  • 5 of Meyer Children's Hospital IRCCS's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Eosinophilic Fasciitis is the condition Meyer Children's Hospital IRCCS studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Eosinophilic Fasciitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Meyer Children's Hospital IRCCS pipeline card: 6 registered trials from official public datasets.Report a data error.